Pfizer strikes an R&D partnership with Flagship's ProFound as it looks for next-gen obesity assets

Drew Armstrong

Executive Editor

Pfizer is opening up another road to the obesity market, announcing a partnership with one of Flagship Pioneering’s startups to identify new molecules and targets …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Pfizer strikes an R&D partnership with Flagship's ProFound as it looks for next-gen obesity assets

Drew Armstrong

Executive Editor

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

Pfizer CEO says opportunities with Trump ‘clearly outweigh’ the risks for pharma

CBER's deputy director departs as staff shakeup continues

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

FDA approves first drug to treat ultra-rare lipid storage disease

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

Pfiz­er strikes an R&D part­ner­ship with Flag­ship's Pro­Found as it looks for next-gen obe­si­ty as­sets

Executive Editor

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Pfizer strikes an R&D partnership with Flagship's ProFound as it looks for next-gen obesity assets